BioPharma Clinical Trials
Hong Kong's Akeso Biopharma Advances Immunotherapy in Biliary Tract Cancer with First Patient Enrolled in Phase III Study of Ivonescimab
Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, c...
November 01, 2024 | News
Hong Kong’s Akeso Biopharma Enrolls First Patient in Pioneering Phase III Trial for Advanced Head and Neck Cancer Therapy
Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (A...
October 31, 2024 | News
Clover Biopharmaceuticals' Non-Adjuvanted RSV Vaccine Candidate SCB-1019 Shows Promising Efficacy and Safety in Head-to-Head Comparison with GSK's AREXVY
- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candi...
October 29, 2024 | News
RiboX Therapeutics Secures FDA IND Clearance for First Circular RNA Therapy, Initiating Clinical Trials for RXRG001
RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, ...
October 28, 2024 | News
LakeShore Biopharma Gains NMPA Approval for Phase III Trial of Simplified Four-Dose Rabies Vaccine Regimen
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developin...
October 28, 2024 | News
MicuRx Achieves Milestone with Successful Phase I Trial of Novel Antibacterial MRX-5 in Australia
Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 in Australi...
October 28, 2024 | News
Corvia Medical’s Atrial Shunt Demonstrates Long-Term Efficacy in Heart Failure Patients: Three-Year Trial Results Published
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced impressive three-year results from its REDUCE LAP-HF II ...
October 28, 2024 | News
South Korea’s Qurient Launches Phase 1 Clinical Trial for Adrixetinib in AML Following FDA IND Clearance
Qurient has announced the commencement of a clinical trial for adrixetinib (formerly named Q702), following the clearance of its investigational new drug (...
October 25, 2024 | News
Pierre Fabre Doses First Patient with PFL-002/VERT-002, a Novel c-MET Degrader for MET-Altered Cancers
PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET, with the potential to be...
October 25, 2024 | News
Taiwan’s Caliway Biopharmaceuticals Completes Final Phase 2b Study of CBL-514, First Injectable for Large-Area Fat Reduction
The first and only lipolytic injectable for large area – CBL-514's last Phase 2b study has been completed Both CBL-514 Phase 2b&nbs...
October 24, 2024 | News
Hope Medicine’s HMI-115 Shows Significant Pain Reduction in Endometriosis Phase 2 Trial
HMI-115 has demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-m...
October 24, 2024 | News
RAPT Therapeutics Boosts Drug Development Efficiency with INTEGRA Biosciences’ Pipettes for Cancer and Inflammatory Disease Research
RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small...
October 23, 2024 | News
SGS Launches Pioneering CDISC Open Rules Consultancy to Accelerate Clinical Trial Submissions
SGS, the world’s leading testing, inspection and certification company, has today launched its pioneering ‘CDISC Open Rules Consultancy’,...
October 23, 2024 | News
Recursion Doses First Patient in Phase 2 Trial of REC-3964, a Novel Non-Antibiotic Treatment for Recurrent C. difficile Infection
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a uni...
October 23, 2024 | News
Most Read
- Lack of Regular Screening Fuels Rise in Late-Stage Breast Cancer in Hong Kong, New Report Reveals
- BIOCHINA 2025: Connecting Global Innovators with China's Leading Biotech Firms
- Leon Wyszkowski, President of Analytical Services, Discusses Thermo Fisher's Strategic Move: Expanding Bioanalytical Capabilities in Europe with New Sweden Lab
- The Role of Policy and Public Health Initiatives in Addressing Women's Cancer Care in Asia
- Redefining Patient Safety in the Age of Healthtech
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
